Latest Drug Delivery News

Page 2 of 6
Noxopharm’s Sofra™ oligonucleotides, delivered via InhaTarget’s inhalable lipid nanoparticles, achieved a significant reduction in lung inflammation in preclinical models, broadening Sofra’s therapeutic reach and delivery versatility.
Ada Torres
Ada Torres
27 Apr 2026
Noxopharm signed a strategic MoU with Tezcat Biosciences, published major Sofra RNA research, and appointed Dr Olivier Laczka as CEO, while reporting positive safety data from its HERACLES trial and improving cash flow.
Ada Torres
Ada Torres
24 Apr 2026
Argent BioPharma has finalized the acquisition of CannPal Animal Therapeutics, securing a Phase 3 veterinary epilepsy asset with near-term commercial prospects and an option to acquire the Neuvis® drug delivery platform, enhancing its neurological portfolio and U.S. market ambitions.
Ada Torres
Ada Torres
13 Apr 2026
EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.
Ada Torres
Ada Torres
18 Mar 2026
Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.
Ada Torres
Ada Torres
16 Mar 2026
EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.
Ada Torres
Ada Torres
13 Mar 2026
EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.
Ada Torres
Ada Torres
10 Mar 2026
LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.
Ada Torres
Ada Torres
5 Mar 2026
PYC Therapeutics has successfully closed its retail entitlement offer, raising approximately $47 million at $1.50 per new share with a 40% take-up rate. New shares are set to begin trading on the ASX from 9 March 2026.
Ada Torres
Ada Torres
4 Mar 2026
Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.
Ada Torres
Ada Torres
2 Mar 2026
Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.
Ada Torres
Ada Torres
27 Feb 2026
Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.
Ada Torres
Ada Torres
24 Feb 2026

Browse the archive

Full archive